Martínez Gorostiaga Javier, Echevarría Orella Enrique, Calvo Hernáez Begoña
Organización Sanitaria Integrada de Álava. OSI Araba. Osakidetza. Vitoria-Gasteiz. España.
Departamento de Fisiología. Facultad de Farmacia. Universidad del País Vasco (UPV/EHU). Vitoria-Gasteiz. España.
Rev Esp Salud Publica. 2018 Aug 16;92:e201808047.
The proton pump inhibitors (PPI) anti-ulcer drugs are one of the most prescribed pharmacological groups in primary care. The objective of the work was to know the prescription of PPI in a Primary Care Area, the Araba district of the Basque Health Service, to advise family doctors about its correct use, and encourage the prescription of the most efficient PPIs.
Descriptive study of 200 family doctors PPI prescription at the Araba district of the Basque Health Service. Data were obtained from prescriptions billed by pharmacies between 2009 and 2014. We analyzed the expenses and DHD (DDD per 1000 inhabitants/day) of PPIs dispensed and the omeprazole relative uptake compared to other PPIs. Statistical analysis was performed with IBM SPSS v23® statistic software.
IBP prescription increased by 23.75% (from 78.14 DHD in 2009 to 96.70 DHD in 2014). Their use was much higher than that of other European countries. In the same period, omeprazole relative prescription compared to other PPIs decreased by 4.56% (omeprazole % Defined daily dose (DDD) went from 74.67% in 2009 to 70.11% in 2014). The overall expenditure of these medicines decreased by 17.60%.
There is an overall increase in the prescription of PPIs, although the expenses have decreased due to price drop. Likewise there is a decrease in the relative consumption of omeprazole, although the indications approved had not changed. PPIs prescription should be done with caution since their unjustified high use in the prevention of gastropathy increases the risk of inappropriate prescriptions. The most recommended PPI continues to be omeprazole.
质子泵抑制剂（PPI）类抗溃疡药物是基层医疗中处方量最大的药物类别之一。本研究旨在了解巴斯克卫生服务机构阿拉瓦地区基层医疗领域PPI的处方情况，为家庭医生提供正确用药建议，并鼓励使用效率最高的PPI。
对巴斯克卫生服务机构阿拉瓦地区200名家庭医生开具的PPI处方进行描述性研究。数据来源于2009年至2014年药店计费的处方。我们分析了PPI的费用和每1000居民每日限定剂量数（DHD）以及奥美拉唑与其他PPI相比的相对使用量。使用IBM SPSS v23®统计软件进行统计分析。
IBP处方量增加了23.75%（从2009年的78.14 DHD增至2014年的96.70 DHD）。其使用量远高于其他欧洲国家。同期，与其他PPI相比，奥美拉唑的相对处方量下降了4.56%（奥美拉唑的限定日剂量百分比从2009年的74.67%降至2014年的70.11%）。这些药物的总支出下降了17.60%。
PPI的处方总量有所增加，尽管因价格下降费用有所减少。同样，奥美拉唑的相对消费量有所下降，尽管其获批适应症未变。PPI的处方应谨慎进行，因为在预防胃病方面不合理的高使用量会增加不适当处方的风险。最推荐的PPI仍然是奥美拉唑。
